Jacob A. Udell

Jul 18, 2024 | medscape.com | Nihar R. Desai |Jacob A. Udell

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nihar R. Desai, MD, MPH: Hello. I'm Dr Nihar Desai from the Yale School of Medicine. Welcome to season 1 of the Medscape InDiscussion: Cardiorenal Metabolic Syndrome podcast series. Today we're discussing novel therapies and we're going to focus on the sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Apr 7, 2024 | jamanetwork.com | Alexander Peikert |Brian Claggett |Jacob A. Udell |Jacob Joseph

Key PointsQuestion  Does the antibody response to high-dose trivalent compared with standard-dose quadrivalent influenza vaccine differ among patients with recent myocardial infarction or hospitalization for heart failure, and are immune responses associated with adverse clinical outcomes?

Feb 26, 2024 | onlinelibrary.wiley.com | Natalie Dayan |Jacob A. Udell

Since the first published case report of a successful in vitro fertilisation (IVF) pregnancy in 1978,1 the use of assisted reproductive technologies (ART) has markedly increased, accounting for 1% of births in Canada, and rising.2 These procedures have allowed couples struggling with infertility, single-birthing parents and same-sex couples to realise their dreams of procreation.

Feb 22, 2024 | jacc.org | Jacob A. Udell |Mark C. Petrie |W. Schuyler Jones |Stefan Anker

Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure (HF) in patients with HF with reduced or preserved left ventricular ejection fraction (LVEF), type 2 diabetes and high cardiovascular risk, and chronic kidney disease.1 Patients with acute myocardial infarction (MI), especially those presenting with left ventricular systolic dysfunction (LVSD) or signs or symptoms of congestion, are at risk for in-hospital and long-term adverse...

Feb 22, 2024 | jacc.org | Jacob A. Udell |Mark C. Petrie |W. Schuyler Jones |Stefan Anker

Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure (HF) in patients with HF with reduced or preserved left ventricular ejection fraction (LVEF), type 2 diabetes and high cardiovascular risk, and chronic kidney disease.1 Patients with acute myocardial infarction (MI), especially those presenting with left ventricular systolic dysfunction (LVSD) or signs or symptoms of congestion, are at risk for in-hospital and long-term adverse...